Nonalcoholic fatty liver disease (NAFLD), now renamed Metabolic dysfunction-associated fatty liver disease (MAFLD), refers to the accumulation and inflammation of fat in liver cells not linked to alcohol consumption. MAFLD often is linked with metabolic dysfunctions such as insulin resistance, dyslipidemia, obesity, and hypertension. As MAFLD progresses it may develop into nonalcoholic steatohepatitis (NASH), leading to liver fibrosis or even cirrhosis where scar tissue replaces healthy cells which threatens liver function – potentially increasing mortality risks. In the US, nearly 40% of adults are affected by MAFLD. Alarmingly, fewer than 5% of those with MAFLD are aware they have the condition. Additionally, between 12% to 14% of these individuals also suffer from Steatohepatitis, a condition that can further develop into advanced fibrosis, cirrhosis, and hepatocellular carcinoma.

Nonalcoholic fatty liver can lead to major health risks without clear symptoms. Request a FREE consultation for Fatty Liver Testing below.

Who Should Be Tested for Nonalcoholic Fatty Liver Disease?

Testing for MAFLD is recommended for individuals who exhibit risk factors or symptoms that may suggest liver inflammation. Primary candidates for MAFLD testing include:

• Overweight or Obese Individuals: Obesity significantly increases the risk of MAFLD, and thus those with a higher body mass index (BMI) should be considered for testing.
• Abnormal Liver Enzymes:  Elevated liver enzyme levels such as Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST), may signal inflammation or injury to the liver, possibly as a result of NAFLD.
• Individuals with Prediabetes or Type 2 Diabetes: Diabetes can be a significant risk factor for the development of NAFLD, so diabetic patients should be screened.
• People with Cardiometabolic Risk Factors: Those with two or more cardiometabolic risk factors such as hypertension, dyslipidemia (abnormal blood lipids), and insulin resistance should undergo testing.
• Presence of Hepatic Steatosis on Imaging: If imaging tests like ultrasound or MRI reveal fatty deposits in the liver (hepatic steatosis), it suggests the presence of MAFLD, warranting further assessment.
• Individuals Exhibiting Signs of Advanced MAFLD or NASH: Individuals experiencing symptoms like persistent fatigue, right upper abdominal pain, or unexplained weight loss could have progressed to a severe form of MAFLD or nonalcoholic steatohepatitis (NASH). Those experiencing these symptoms should get tested as soon as possible.

Due to rising obesity and metabolic syndrome rates, increasing awareness and undertaking proactive testing within at-risk populations is crucial in order to detect and manage MAFLD early on.

Tests to Diagnose MAFLD

MAFLD is becoming an increasing concern, particularly among individuals with certain risk factors. To accurately diagnose this condition and its severity, various blood tests, imaging scans, and advanced diagnostic methods are employed to confirm its presence while also providing essential data regarding liver health as well as fat accumulation and inflammation levels.

1. Blood Tests: Liver function tests measure liver inflammation.
2. Imaging Tests: Ultrasound, CT scan, and MRI provide visual insights into the liver’s appearance.
3. Advanced Tests: Transient elastography quantifies liver fat and assesses liver stiffness, though its reliability can decrease with substantial liver fat. In cases of suspected advanced liver disease, a liver biopsy might be recommended.

Treatment of MAFLD

Treatment for MAFLD primarily focuses on lifestyle changes and the management of associated health conditions. Here are the common treatments and interventions:

Lifestyle Modifications

• Dietary Changes: Adopting a balanced diet that’s low in saturated fats, trans fats, and refined sugars. People with MAFLD would benefit most from adding more fruits, vegetables, whole grains, and lean proteins into their daily eating plans.
• Physical Activity: Engaging in regular exercises such as brisk walking or cycling helps people shed unwanted weight in turn decreasing liver fat accumulation and stimulating metabolic function.
• Weight Loss: Even modest weight loss can help decrease liver fat and inflammation. Reducing body weight by 3-5% could result in less liver fat accumulation; 10% can potentially alleviate inflammation issues in your liver.

Management of Accompanying Conditions:

• Blood Sugar Control: Diabetes or prediabetics often need medications to control their blood sugar. 
• Lowering Cholesterol and Triglycerides: Lipid-lowering drugs may be beneficial in managing elevated levels of these blood lipids.
• Blood Pressure Management: Controlling blood pressure is vital, and medication may be prescribed if lifestyle modifications alone don’t suffice.
• Medication: While no FDA-approved medications specifically target MAFLD, certain therapies such as Vitamin E, pioglitazone, and obeticholic acid have shown promise for subgroups of MAFLD or NASH patients with evidence of liver fibrosis.

Advanced Treatment Options:

•  Individuals suffering from more advanced forms, Nonalcoholic Steatohepatitis (NASH), or with cirrhosis should consider liver transplantation as a last resort treatment option.

Regular monitoring by a healthcare professional and routine liver function tests are also essential in tracking the disease’s progression and adjusting treatments as necessary.

Are you taking control of your metabolic health? With the prevalence of Metabolic dysfunction-associated fatty liver disease (MAFLD) on the rise, early detection is crucial to prevent its progression and associated complications. Our comprehensive MAFLD testing offers a thorough evaluation of your liver’s health and potential metabolic risks. Leveraging state-of-the-art diagnostic tools and a team of dedicated medical professionals, we ensure accurate and timely results. Don’t leave your health to chance. Stay one step ahead with our advanced MAFLD testing and invest in a future of wellness and peace of mind. Request a free consultation today!